For the last decade, large healthcare companies have systematically acquired more and more parts of the healthcare ecosystem in an effort to create vertically integrated juggernauts. Healthcare would become more efficient, administrative friction would decline, and incentives would align more cleanly. Over time, the underlying economics of healthcare would become more manageable.
Q1 earnings season delivered a more complicated reality.
Utilization is still elevated. Pharmaceutical costs are still climbing. Labor pressure remains intense. Providers are still struggling with margins. And despite all the promises around efficiency, interoperability, automation, and coordinated care, many organizations are still pulling the same operational levers they always have: slower claims payment, more utilization management, more reviews, more denials, and more appeals.
Slower claims payment is becoming a margin lever
The clearest operational pattern this quarter was movement in days claims payable.
- UnitedHealth increased to 48.6 days from roughly 45 days in Q4.
- Elevance moved to 46.6 days — more than 5 days higher sequentially.
- Centene increased to 48 days from 46 days the previous quarter.
- CVS moved from 38.9 to 42.9 days.
- Humana remained materially faster than peers at 33.9 days, though still up sequentially from 31.9 days.
At this point, “temporary working capital management” is starting to look suspiciously permanent.
Holding claims longer immediately improves working capital and operating flexibility without solving the underlying cost problem. But it also means billion-dollar payors are increasingly holding onto money that providers have already earned while hospitals and physician groups operate on much thinner margins themselves.
A few additional days may look minor inside a massive insurance balance sheet. For providers trying to manage payroll, capital projects, staffing shortages, and inflationary pressure, it is very real money moving very slowly. Evidently, the float works in one direction.
Automation is becoming the new payor trust campaign
Another striking pattern this quarter was how much time payors spent talking about interoperability, automation, simplification, consumer experience, reducing friction, and AI-enabled workflows. CVS was the clearest example.
The company repeatedly emphasized faster prior authorization decisions, real-time processing, interoperability, and reducing administrative burden.
Administrative burden itself is not new. Providers have long understood utilization management, prior authorization, and review processes as core financial tools inside managed care. What feels different now is the emerging narrative around reducing that burden.
Providers are sophisticated enough to recognize that automation can improve approval speed for low-complexity requests while leaving the more operationally painful utilization management battles intact. In a fully digital workflow environment, “easy yes” approvals naturally move faster. That improves metrics quickly.
The harder question is whether the industry is meaningfully reducing administrative burden or simply removing the parts that were never especially burdensome to begin with.
And the timing of these “trust” narratives is not accidental.
Legislators and regulators are increasingly questioning vertically integrated healthcare models, particularly around PBMs, ownership concentration, and incentive alignment. Tennessee’s recent legislative action only accelerated that conversation.
So while payors describe these investments as consumer-focused simplification, providers increasingly hear something else: more automation, more centralized control, and more operational leverage.
The industry increasingly seems to believe administrative burden feels better if you automate it first.
Medicare Advantage is still the pressure point
For all the differences across these earnings calls, Medicare Advantage pressure remains the common denominator.
Humana said it most directly. Membership is growing, but the newer members are arriving with higher acuity and higher costs. Star ratings pressure continues to compress the revenue side of the equation while utilization continues to pressure the expense side.
Centene’s quarter raised similar questions. Health benefits ratio improved dramatically even while Marketplace and Medicare Advantage enrollment trends suggested the healthier members may already be leaving.
And then there was Cigna.
While other organizations spent the quarter discussing how to better manage Medicare Advantage pressure, Cigna effectively demonstrated the results of a different strategy entirely: leave.
The company sold off its Medicare Advantage business, improved margins almost immediately, and then announced plans to exit the Exchange market as well.
Providers across the country are increasingly evaluating the same question in their own contracts. When does participation stop making economic sense?
Meanwhile, Kaiser Permanente and Risant Health continue to argue that highly integrated value-based care remains the long-term answer to affordability and coordination. But even there, operating margins compressed from 2.9% to 2.1% despite scale, integration, and aligned incentives.
Kaiser is effectively the healthcare industry’s most mature large-scale experiment in aligned incentives and integrated delivery. If even that model is operating under sustained pressure from labor, pharmaceutical expense, utilization, and care delivery inflation, the broader industry should pay attention.
Oscar may have exposed the affordability contradiction most clearly
Oscar’s quarter looked radically different from the rest of the market. No discussion of slowing payments. No interoperability campaign. No operational restructuring narrative. Just growth.
Revenue jumped from $3.0 billion to $4.6 billion. Membership increased from roughly 2 million to more than 3.1 million lives. Net income climbed from $275 million to $679 million. Most notably, MLR improved to 70.5%, an extraordinary number in this environment.
Oscar’s argument is fundamentally simpler than the large integrated payors: consumers want to shop for healthcare like retail products. At least financially, that strategy appears to be working, but the optics become complicated quickly. True, it’s just the Q1 MLR and by year-end it will probably be somewhere in the 80s, and of course rebate protections ensure that Oscar will give refunds on any premium overpayments. But didn’t we already talk about billion-dollar companies holding on to money that’s needed to pay for near-term expenses?
If affordability remains one of the defining healthcare concerns in the country, consumers may eventually begin asking harder questions about premium pricing, deductibles, administrative burden, and how much of each premium dollar actually reaches care delivery.
Three things providers and health systems should take away from Q1
1. Administrative burden is getting a rebrand.
Utilization management, prior authorization, review processes, appeals, and claims oversight have always functioned as financial tools inside managed care. What changed in Q1 was the amount of effort payors spent repositioning parts of that infrastructure as “simplification,” “automation,” and “reduced friction.”
Providers generally understand the distinction because they are the ones experiencing the burden operationally.
Removing low-complexity approvals or accelerating “easy yes” workflows may improve operational metrics and public perception without materially changing the day-to-day friction attached to high-cost and high-complexity care.
The industry increasingly appears focused on reducing the appearance of administrative burden and less on meaningfully reducing the burden itself.
2. Scrutiny on vertical integration is expanding.
CVS, Kaiser, Risant, and others are all making slightly different versions of the same argument: integrated systems improve affordability, coordination, and consumer experience.
Regulators, legislators, and providers increasingly appear unconvinced that the incentives always align cleanly in practice. That debate is now shaping legislation, market strategy, acquisitions, partnerships, and provider negotiations.
3. The economics of care delivery are pressuring every model.
Whether the company is a traditional payor, integrated delivery system, value-based care organization, or an exchange-focused insurer, everyone is dealing with:
- Elevated utilization
- Pharmaceutical inflation
- Labor pressure
- Higher acuity
- Affordability concerns
The strategies differ, but the pressure doesn’t, and that may ultimately be the most important takeaway from Q1.
Final thoughts
No one appears to have fully solved the underlying economics of healthcare. Some organizations are simply managing the pressure more effectively than others.
If every major player in healthcare is still under pressure after a decade of consolidation, integration, automation, and value-based care initiatives, maybe it’s time to ask whether the industry is actually managing costs or just redistributing them.
If the answer is redistribution, providers and health systems may need to think differently about where they participate, which contracts they keep, how much administrative burden they absorb, and what kind of healthcare economy they are helping sustain.
